Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
Xiao-Ran LiuXiangming ChengFeng XieKun LiYongcan ShiBin ShaoXu LiangFengling WanShidong JiaYue ZhangYiqiang LiuHuiping LiPublished in: British journal of cancer (2024)
level is associated with a favourable tumour immunity and a better PFS of HER2-targeting therapy in MBC patients.